by
John R. Fischer, Senior Reporter | June 07, 2021
GE has partnered with the American College of Cardiology to help advance AI and digital technology in cardiac care
GE Healthcare has joined the American College of Cardiology’s Applied Health Innovation Consortium to help advance the reach and impact of AI and digital technology in cardiology.
The manufacturer will provide its expertise and technology for cardiovascular care to help the consortium develop new strategies around risk prediction and decision-making in cardiac care. "Making precision health a reality requires digital technology, such as AI, to address the challenges that exist in cardiology today," Eigil Samset, chief technology scientist for cardiology solutions at GE Healthcare, told HCB News.
The collaboration will initially focus on challenges around atrial fibrillation management and other care pathways, including for coronary artery disease, valvular heart disease and heart failure. The aim of the consortium is to define challenges, develop AI models and apply research findings to clinical practice that will strengthen clinical workflows around cardiac care.
Among its solutions for advancing cardiac care is GE Healthcare’s Edison platform, which is the basis for many of the company’s AI solutions. The solution applies analytics and advanced algorithms to generate clinical, operational and financial insights. Among its offerings for cardiology are Auto EF 2.0, which uses view recognition to simplify ejection fraction assessment; and PCI ASSIST, software that helps increase the accuracy of stent placement even in the most complex cases at no extra dose.
"The future of healthcare is about shifting our focus from solely treating disease to preventing disease and enhancing wellness, and this collaboration with the ACC is one way we can accomplish the goal of making cardiology care more precise, personal and efficient," said Samset.
ACC recently
partnered with BioIntelliSense on cardiac health in a partnership that combined ACC’s clinical expertise with BioIntelliSense’s BioSticker and medical-grade BioButton wearable devices for early detection of adverse vital sign trends in cardiac patients. It also
teamed up with Butterfly Network to design clinical trials and care pathways to address challenging heart diseases and accelerate the adoption of point-of-care ultrasound in cardiovascular care.
